ZynexZYXI
Market Cap: 284M
About: Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.
Employees: 1,101
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
28% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 18
13% more capital invested
Capital invested by funds: $105M [Q4 2023] → $119M (+$13.7M) [Q1 2024]
4% more funds holding
Funds holding: 112 [Q4 2023] → 117 (+5) [Q1 2024]
1.4% more ownership
Funds ownership: 28.52% [Q4 2023] → 29.92% (+1.4%) [Q1 2024]
41% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 44
66% less call options, than puts
Call options by funds: $520K | Put options by funds: $1.52M
Research analyst outlook
6 Wall Street Analysts provided 1 year price forecasts over the past 6 months
6 analyst ratings
RBC Capital Shagun Singh | 34%upside $12 | Outperform Maintained | 26 Jul 2024 |
HC Wainwright & Co. Yi Chen | 79%upside $16 | Buy Maintained | 26 Jul 2024 |
RBC Capital Shagun Singh | 68%upside $15 | Outperform Reiterated | 14 Jun 2024 |
HC Wainwright & Co. Yi Chen | 135%upside $21 | Buy Reiterated | 1 May 2024 |
RBC Capital Shagun Singh | 68%upside $15 | Outperform Maintained | 1 Mar 2024 |
Financial journalist opinion
Based on 9 articles about ZYXI published over the past 30 days